olanzapine / Generic mfg. - LARVOL DELTA

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND) (ASH 2025) - P3 | "Introduction:Selinexor (S) is an oral selective exportin 1 inhibitor approved in relapsed multiple myeloma (MM) incombination with bortezomib (V) and dexamethasone (d)...Patients received ondansetron 8mg immediately prior to, and 8-hours following each S dose.Additional ondansetron and low-dose olanzapine were used as required for break-through nausea andvomiting...In this randomized phase III study, the addition of low-dose S to R maintenance following ASCT did notresult in a significant PFS benefit compared to R alone in NDMM. Although a higher CR rate was observedwith SR, this came at the cost of increased toxicity, including more infections, cytopenias andgastrointestinal AEs. Quality of life, as assessed by EORTC QLQ-C30 and MY20, was comparable betweenarms."

Clinical • P3 data • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation • XPO1

PSYCHOTIC FEATURES IN MYHRE SYNDROME: EVIDENCE FOR BROADER NEUROPSYCHIATRIC SURVEILLANCE (WRMC 2026) - "Presently, she lives in a group home due to her complex needs but has been asymptomatic while taking olanzapine...She is currently on quetiapine and divalproex, with stable symptom control for 1.5 years...TGF-β signaling not only influences neurodevelopment but also plays a role in immune regulation, which is thought to contribute to the pathophysiology of psychosis and schizophrenia. Although additional cases are needed to confirm our observations, psychosis may be a component of the neurodevelopmental phenotype of Myhre syndrome, underscoring the importance of prompt psychiatric evaluation and intervention."

Anorexia • Autism Spectrum Disorder • Bipolar Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Insomnia • Mental Retardation • Otorhinolaryngology • Psychiatry • Schizophrenia • Sleep Disorder • SMAD4 • TGFB1

EMERGING PSYCHOSIS WITH AI-FOCUSED DELUSIONS: CASE STUDY OF DIAGNOSTIC COMPLEXITY IN A YOUNG ADULT (WRMC 2026) - "During hospitalization, treatment with olanzapine and valproic acid led to gradual mood stabilization and decreased behavioral disorganization, though AI-themed delusional beliefs persisted...Such presentations raise unique diagnostic challenges, as clinicians must distinguish between psychosis, substance-induced exacerbation, and culturally mediated speech. Cross-referencing chatbot outputs may provide a novel strategy to clarify whether AI-related content reflects true delusional thinking or external influences thereby guiding more accurate diagnosis and treatment."

Case study • Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • General Anxiety Disorder • Infectious Disease • Mental Retardation • Mood Disorders • Novel Coronavirus Disease • Psychiatry • Suicidal Ideation

Trends in Atypical Antipsychotic Use Among Children and Adolescents With Depressive Disorders in Korea. (PubMed, J Korean Med Sci) - "The use of AAPs has progressively increased among Korean children and adolescents with depressive disorders, particularly among those with psychiatric comorbidities. Further studies are needed to establish safer and more evidence-based AAP treatments for depressive disorders in children and adolescents."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

A case of diverse psychiatric and functional impairments following immune checkpoint inhibitor therapy. (PubMed, PCN Rep) - "A 64-year-old man with Stage IV gastric cancer receiving nivolumab developed impaired consciousness, delusions, and dissociative behavior, and reduced instrumental activities of daily living during and after ICI therapy...Steroid pulse therapy and antipsychotics (risperidone, later olanzapine) improved symptoms...In patients undergoing ICI therapy, new-onset psychiatric symptoms should raise suspicion for irAEs. Timely multidisciplinary intervention is essential for accurate diagnosis and effective symptom management."

Checkpoint inhibition • Journal • Alzheimer's Disease • CNS Disorders • Dementia • Gastric Cancer • Oncology • Psychiatry • Solid Tumor

Body mass index but not percentage weight loss was associated with the race/ethnicity of patients with advanced lung cancer: a cross-sectional study. (PubMed, Ann Palliat Med) - "In patients with advanced lung cancer, BMI and total weight loss but not percentage change in weight was significantly associated with self-identified race/ethnicity at the time of Palliative Medicine consultation. On multivariate analysis, the percentage loss in weight was significantly influenced by the weight at first encounter but not race/ethnicity. Racial/ethnic variations in BMI but not percentage weight loss should be accounted for when diagnosing cancer cachexia and more research is needed."

IO biomarker • Journal • Observational data • Retrospective data • Cachexia • Lung Cancer • Oncology • Palliative care • Solid Tumor

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Roswell Park Cancer Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Anorexia • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Carcinoma of Unknown Primary

Clinical predictors of short-term treatment response in stupor: a retrospective study. (PubMed, Front Psychiatry) - "Responders were more likely to receive ECT (χ2 = 6.667, P = 0.010), higher chlorpromazine equivalent doses (|Z| = 3.418, P = 0.001), and olanzapine (χ2 = 4.365, P = 0.037), while inflammatory markers showed no differences. However, these findings are preliminary, limited to two-week outcomes in a modest retrospective sample. The role of inflammation in stupor remains inconclusive, and further studies are warranted to clarify its predictive value."

Journal • Retrospective data • CNS Disorders • Inflammation

Olanzapine Overdose-Induced Bradycardia in a Young Adult With Major Depressive Disorder: A Case Report and Literature Review. (PubMed, Clin Case Rep) - "This case highlights isolated bradycardia as an uncommon but important manifestation of olanzapine toxicity. Clinicians should consider bradycardia in the cardiovascular spectrum of olanzapine overdose and ensure vigilant monitoring to prevent potential complications."

Journal • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Psychotic Risk Associated With Cannabinoid Use: A Case Report of Ekbom-Like Delusional Infestation. (PubMed, Cureus) - "Treatment with olanzapine and psychoeducation was initiated, with gradual symptomatic improvement. This case report aimed to describe an Ekbom-like somatic presentation within a probable cannabis-induced psychotic disorder and to highlight the diagnostic value of structured clinical assessment, laboratory testing and normal neuroimaging findings in excluding secondary causes. This case underscores the need to consider substance-induced psychosis in patients presenting with delusional infestation, and it reinforces the importance of early recognition, careful differential diagnosis and counselling toward substance cessation to improve prognosis."

Journal • CNS Disorders • Dermatology • Pruritus • Psychiatry • Restless Legs Syndrome

Use of antipsychotics in children and adolescents in Spain, 2015-2023: a real-world, population-based study. (PubMed, Span J Psychiatry Ment Health) - "AP prescriptions and patients treated among Spanish youth increased significantly between 2015 and 2023, with notable differences by age and sex. While total CED rose, treatment intensity per patient remained relatively stable. Future studies should investigate the clinical indications for these prescriptions as well as the outcomes associated with AP use in children and adolescents."

Journal • Real-world evidence • CNS Disorders

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients (clinicaltrials.gov) - P3 | N=40 | Recruiting | Sponsor: Tanta University | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Jun 2024 ➔ Jun 2026 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Metabolic Disorders • Psychiatry • Schizophrenia

Risk of neutropenia-related hospitalisation among clozapine initiators. (PubMed, BMJ Ment Health) - "Despite removal of the REMS programme, it is important for prescribers to monitor patients for neutropenia after initiating clozapine."

Journal • Agranulocytosis • CNS Disorders • Granulocytopenia • Hematological Disorders • Neutropenia • Psychiatry • Schizophrenia

Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective Disorder. (PubMed, Clin Drug Investig) - P3 | "TV-44749 administration resulted in a sustained release profile and comparable exposure to daily therapeutic doses of oral olanzapine over a monthly dosing interval. The TV-44749 systemic safety profile was consistent with approved oral olanzapine. The local tolerability was acceptable, and there were no PDSS events. These results contributed to the dose selection of TV-44749 in a phase III study evaluating its efficacy and safety in adults with schizophrenia (SOLARIS; NCT05693935)."

Journal • PK/PD data • Anesthesia • CNS Disorders • Pain • Psychiatry • Schizophrenia

Memantine Use in Prolonged Cognitive Sequalae in Pediatric Anti-N-methyl-D-aspartate Receptor Encephalitis: A Three-year Follow-up Case Report and Brief Review. (PubMed, Clin Psychopharmacol Neurosci) - "The patient received immunotherapy including intravenous methylprednisolone, intravenous immunoglobulin, and rituximab, as well as concurrent psychotropics, including valproate and olanzapine/aripiprazole. While 20 mg/day dose of memantine was administering during 6 months, marked improvement was observed in her verbal fluency, academic functioning, and social engagement, that may be associated with post-acute initiation of memantine alongside conventional treatments. This case highlights the evolving understanding of post-autoimmune cognitive rehabilitation and discusses current evidence and theoretical rationale supporting memantine use in complementary treatment of prolonged cognitive dysfunction in the pediatric anti-NMDAR encephalitis."

Journal • Cataplexy • CNS Disorders • Cognitive Disorders • Immunology • Pediatrics • Psychiatry

Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin®), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report. (PubMed, Cureus) - "The patient received prophylactic antiemetic therapy with olanzapine (5 mg after dinner for six days), palonosetron, and fosnetupitant during DA-R-EPOCH therapy. A four-drug antiemetic regimen, including olanzapine, supported the feasibility of preventing CINV in this case involving DA-R-EPOCH therapy. However, adverse events potentially related to olanzapine were observed, suggesting the need for further investigation into its optimal dosage."

CINV • Journal • B Cell Lymphoma • Chemotherapy-Induced Nausea and Vomiting • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Disentangling violence in schizophrenia: Interactions between symptom trajectories, conduct disorder, and pharmacotherapy. (PubMed, Schizophr Res) - "These findings highlight the importance of interactions among symptoms, conduct disorder, and medication in determining violence. They also point to the multifactorial etiology of violence in patients with schizophrenia and to the need for tailored treatment strategies to effectively reduce violence, especially in high-risk population."

Journal • Behavior Disorders • CNS Disorders • Depression • Psychiatry • Schizophrenia

Novel selective morpholine trace amine-associated receptor 1 partial agonists show promising preclinical effects for neuropsychiatric disorders and are well tolerated in healthy volunteers. (PubMed, Mol Psychiatry) - "TAAR1 agonists from a prior amino oxazolines series were studied preclinically and clinically, but development of partial agonist RO5263397 was halted due to poor metabolization by N-glucuronidation in individuals with UGT2B10 splice site mutations...They reduced PCP- and cocaine-induced hyperlocomotion, potentiated olanzapine's effect, partially reversed cocaine-induced facilitation of intracranial self-stimulation and demonstrated anxiolytic-like properties in the stress-induced hyperthermia test...RO6889450 was well tolerated up to 300 mg; at 450 mg, dose-limiting adverse events included postural tachycardia and erythema. Together, these results indicate the translational potential and support further clinical exploration of TAAR1 agonists as a novel therapeutic option for neuropsychiatric disorders, particularly schizophrenia and substance use disorder."

Journal • Preclinical • Cardiovascular • CNS Disorders • Dermatology • Mental Retardation • Psychiatry • Schizophrenia

Olanzapine-induced diabetes presenting as diabetic ketoacidosis with disseminated, atypically manifesting hypervirulent Klebsiella pneumoniae infection (ESCMID Global 2026) - No abstract available

Diabetes • Infectious Disease • Metabolic Disorders • Pneumonia

The efficacy and safety of olanzapine combined with osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 21 L858R mutation: A single-arm, prospective, multicenter clinical study (ChiCTR) - P4 | N=70 | Not yet recruiting | Sponsor: China-Japan Friendship Hospital; China-Japan Friendship Hospital

New P4 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov) - P2 | N=180 | Active, not recruiting | Sponsor: Central Institute of Mental Health, Mannheim | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2027

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Optimizing Antiemetic Support in Anthracycline-Based Chemotherapy for Early Breast Cancer: Protocol for a Prospective Observational Study of Four-Drug Antiemetic Therapy Including Fosnetupitant and Olanzapine. (PubMed, JMIR Res Protoc) - "Four-drug antiemetic therapy, consisting of a neurokinin-1 receptor antagonist (NK1RA), a 5-hydroxytryptamine type 3 receptor antagonist (5-HT3RA), dexamethasone (DEX), and olanzapine (OLZ), is currently recommended for HEC. Data collection is expected to continue until April 2026, and both data collection and analyses are anticipated to be completed in 2027. This study will provide real-world evidence on the effectiveness and safety of a four-drug antiemetic regimen, including FosNTP and OLZ, in patients receiving anthracycline-based HEC and may inform optimal OLZ dosing strategies."

Clinical protocol • Journal • Observational data • Breast Cancer • Chemotherapy-Induced Nausea and Vomiting • Oncology • Solid Tumor

Olanzapine in the treatment of schizophrenia in adolescents - mechanisms of action and therapeutic efficacy. (PubMed, Psychiatr Pol) - "Olanzapine is effective in adolescent psychosis and mania but carries substantial metabolic liability. Given no clear efficacy advantage over other SGAs, it is best positioned as a second-line agent in youth, with preference for monotherapy, cautious dosing, and stringent metabolic monitoring. Evidence for benefits on negative and cognitive symptoms in adolescents remains limited."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Dyslipidemia • Metabolic Disorders • Mood Disorders • Pediatrics • Psychiatry • Schizophrenia

Olanzapine Overdose in an Adult Male Presenting With Altered Sensorium and Pinpoint Pupil: A Case Report. (PubMed, Cureus) - "Prompt clinical evaluation, along with thorough history-taking from patients or family members, is a crucial step in patient management and thereby improving the outcome. Increasing awareness among healthcare providers about toxicity due to olanzapine overdose is an important step for assuring early intervention and improving patient care."

Journal • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Dystonia • Hypotension • Mood Disorders • Movement Disorders • Ophthalmology • Psychiatry • Schizophrenia

STAMD: Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (clinicaltrials.gov) - P1/2 | N=520 | Recruiting | Sponsor: First Affiliated Hospital of Chongqing Medical University | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry